anyone follow cell pathways, clpa?
opinion?
Exisulind, CP-461 and other SAANDs represent a novel class of potential therapeutic agents that target a novel form of cyclic GMP phosphodiesterase (cGMP-PDE). Cell Pathways scientists believe that this enzyme, whose production appears to be selectively increased in precancerous and cancerous cells, interferes with the abnormal cells* ability to process the message telling them to die by apoptosis. By specifically inhibiting the action of the novel cGMP-PDE, SAANDs enable abnormal cells to process an apoptotic signal and commit suicide without affecting normal cells. As a result, side effects normally associated with traditional chemotherapeutic agents, such as severe, dose-limiting neutropenia, nausea, vomiting, hair loss, weight loss, etc., have not been observed with SAANDs technology. In addition, the mechanism of action is independent of a variety of mechanisms that confer resistance to many cancer agents.
curtis |
